(Q24243194)

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Interferon-beta treatment of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Hepatitis B and C viruses and primary liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Bile acids for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Mechanisms of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Interferon for acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Interferon for interferon naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Side effects of alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Ursodeoxycholic acid and chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

1 reference

7 January 2021

Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Effect of Ursodeoxycholic Acid in Acute Viral Hepatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: a double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003181.PUB2

7 January 2021

10.1002/14651858.CD003181.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4333605

Fatcat ID

release_fn6lmnjiyncrbixxppfoobmrou

0 references

OpenCitations bibliographic resource ID

4333605

1 reference